Navigation Links
Isis Reports Financial Results and Highlights for Third Quarter 2010
Date:11/4/2010

-cash stock compensation.  Please refer to the reconciliation of pro forma and GAAP measures, which is explained later in this release.

RevenueRevenue for the three and nine months ended September 30, 2010 was $28.6 million and $82.1 million, respectively, compared to $26.8 million and $89.3 million for the same periods in 2009.  Isis' revenue fluctuates based on the nature and timing of payments under agreements with the Company's partners, including license fees, milestone-related payments and other payments.  Isis recognized new revenue in the first nine months of 2010 in the form of an upfront fee from the Company's new partnership with GlaxoSmithKline (GSK), which is amortized through the first quarter of 2015, milestone payments from GSK, Bristol-Myers Squibb and Achaogen and sublicensing income from Regulus' collaboration with sanofi-aventis.  Although Isis recognized this new revenue, its revenue for 2010 decreased compared to 2009 because the amortization of the upfront fee from the Company's Ortho-McNeil collaboration ended in the third quarter of 2009. Additionally, revenue for the first nine months of 2010 decreased by $2.4 million because Isis is no longer including Regulus' revenue in its 2010 revenue.  

Operating ExpensesOn a pro forma basis, operating expenses for the three and nine months ended September 30, 2010 were $34.6 million and $105.1 million, respectively, compared to $33.6 million and $95.4 million for the same periods in 2009.  The higher expenses in 2010 were primarily due to an increase in costs associated with advancing mipomersen toward its initial regulatory filings for marketing approval planned for the first half of next year and offset in part by an $8.3 million decrease because Isis is no longer including Regulus' operating expenses in its 2010 operating expenses.  On a GAAP basis, Isis' operating expenses from continuing operations for the three and nine m
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. Spherix Reports Second Quarter Earnings
3. Tapestry Reports Second Quarter 2007 Results
4. Callisto Reports on Second-Quarter 2007 Milestones
5. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
6. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
7. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
8. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
9. Biopure Reports on Meeting with the FDA
10. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
11. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... A lot of discussion in the medical community revolves ... injuries, or conditions. As medical science advances, doctors and surgeons ... that they consider to be more cutting edge. Yet, when ... method of treatment that stands out as the best solution ...
(Date:1/23/2015)... 2015  Northwest Biotherapeutics, Inc. (NASDAQ: NWBO )("NW Bio"), ... operable and inoperable solid tumor cancers, announced today that CEO ... Annual Phacilitate Immunotherapy Forum in Washington D.C. ... take place on January 26 at 10:30 a.m. EST at ...
(Date:1/23/2015)... Feffer LLP ( www.hfesq.com ) is investigating potential claims ... or the "Company") (NASDAQ: ADXS ), concerning ... shareholders. On January 21, 2015, an article ... had misrepresented the clinical data for its ADXS-HPV drug ...
Breaking Medicine Technology:No One-Size-Fits-All Remedy for Hernia Correction 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2
... , First-of-its-Kind Study Demonstrates REMICADE More Likely to Maintain ... , , CHICAGO, June 2 New ... with moderately to severely active Crohn,s disease having inadequate ... biologic therapy, were presented at Digestive Disease Week today. ...
... Insights into the Prediction of IBD Using Serology Testing ... Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic ... important serologic marker used in the detection of Crohn,s ... for celiac disease. In an oral presentation yesterday at ...
Cached Medicine Technology:New One-Year Data from REMICADE(R) SONIC Trial Show Sustained Efficacy Compared with Azathioprine in Treatment of Crohn's Disease 2New One-Year Data from REMICADE(R) SONIC Trial Show Sustained Efficacy Compared with Azathioprine in Treatment of Crohn's Disease 3New One-Year Data from REMICADE(R) SONIC Trial Show Sustained Efficacy Compared with Azathioprine in Treatment of Crohn's Disease 4New One-Year Data from REMICADE(R) SONIC Trial Show Sustained Efficacy Compared with Azathioprine in Treatment of Crohn's Disease 5New One-Year Data from REMICADE(R) SONIC Trial Show Sustained Efficacy Compared with Azathioprine in Treatment of Crohn's Disease 6New One-Year Data from REMICADE(R) SONIC Trial Show Sustained Efficacy Compared with Azathioprine in Treatment of Crohn's Disease 7New One-Year Data from REMICADE(R) SONIC Trial Show Sustained Efficacy Compared with Azathioprine in Treatment of Crohn's Disease 8New One-Year Data from REMICADE(R) SONIC Trial Show Sustained Efficacy Compared with Azathioprine in Treatment of Crohn's Disease 9Prometheus Announces New Findings Regarding Patients at Risk for Celiac Disease at DDW 2Prometheus Announces New Findings Regarding Patients at Risk for Celiac Disease at DDW 3
(Date:1/22/2015)... January 23, 2015 Angelweddingdress is a famous ... invites its customers to follow it on Facebook, Twitter, and ... Valentine’s Day gift. Angelweddingdress draws a lottery every week. , ... to Feb. 28, 2015. Click Angelweddingdress homepage for ...
(Date:1/22/2015)... 23, 2015 AngelWeddingDress, the premier women’s ... maternity wedding dresses. View website of AngelWeddingDress.com ... for maternity wedding dresses online for a bridal party. ... high quality for them. Its maternity wedding dresses are ...
(Date:1/22/2015)... January 22, 2015 Juvent Sports ( ... the 2015 PGA Merchandise Show to bestow a Juvent ... female amateur golfer, Arlene McKitrick. The award commemorated and ... golf tournament win. She won her first amateur tournament ...
(Date:1/22/2015)... New York, New York (PRWEB) January 22, 2015 ... filed after Fresenius Medical Care recalled its GranuFlo ... the federal multidistrict litigation underway in U.S. District Court, ... an Order dated January 20th, the Court has remanded ...
(Date:1/22/2015)... 2015 For over 20 years, Dr. David Cruz ... Vista area has treated just about every type of injury ... And for those same twenty-plus years, the team at ... injuries with the best possible doctor. With the combined ...
Breaking Medicine News(10 mins):Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2
... giants Cadbury have to pay heavily for the salmonella ... failed to inform the concerned authority about the possible ... of chocolates at their factory. They had supplied these ... many consumers. This was the breach of General Food ...
... It is a known fact that alcohol abuse and/or ... damage. //It is also known that women, more than ... a shorter period of drinking and with less overall ... also sustain greater cognitive damage than male alcoholics. ...
... achieving one of today’s Science greatest goals: allowing humans to ... well as from the UGR, researchers from the Spanish universities ... in this study, concluding that the consumption of melatonin – ... and present in many types of food – delays the ...
... has lodged a complaint with the West Bengal Human ... a patient died because the management// allegedly stopped medication ... 57, died on Saturday at the Mission of Mercy ... April 18 with diabetes, abdominal problem and cardiac ailments. ...
... Rajasthan will be fitted with an electronic biometric attendance system ... initially installed in a few primary schools, but later will ... first be installed in 15 schools of Jaipur and five ... already reached Bikaner. Initially, it would be used on an ...
... article published by the British Medical journal reveals that there has ... in the Asian region. This has become a// major strain on ... report the number of cases are expected to climb at the ... 156 to 100,000 as compared to 164 to 100,000 in the ...
Cached Medicine News:Health News:Cadbury Indicted on Salmonella Scare 2Health News:Cognitive Problems Occur More Rapidly in Female Alcoholics Than in Males 2Health News:Cognitive Problems Occur More Rapidly in Female Alcoholics Than in Males 3Health News:High Melatonin can Help Delay Ageing 2Health News:NRI Doctor Protests Patient's Death in Kolkata Hospital 2Health News:Cancer Time Bomb Threatening Economic Infrastructure 2